|
Feb 8
|
MERCK CANADA ANNOUNCES COLLABORATION WITH VECTOR INSTITUTE TO FURTHER ADVANCE ITS ARTIFICIAL INTELLIGENCE CAPABILITIES AND DRIVE INNOVATION IN HEALTHCARE
|
|
Feb 7
|
2024 Promises To Bring Pharmaceutical Breakthroughs On The Oncology Front
|
|
Feb 6
|
Merck (MRK) Unit to Buy Elanco's Aqua Business for $1.3B
|
|
Feb 5
|
Insider Sell: President, U.S. Market Johannes Oosthuizen Sells 18,959 Shares of Merck & Co ...
|
|
Feb 5
|
Merck to Buy Elanco’s Aqua Business for $1.3 Billion
|
|
Feb 5
|
What a $200 Billion Blockbuster Drug Reveals About Big Pharma’s Playbook
|
|
Feb 5
|
Merck Animal Health to Acquire Elanco’s Aqua Business
|
|
Feb 5
|
Elanco Announces Sale of Aqua Business for $1.3 Billion
|
|
Feb 5
|
Investors more bullish on Merck (NYSE:MRK) this week as stock rises 4.2%, despite earnings trending downwards over past three years
|
|
Jan 16
|
Merck (MRK) Stock Moves -0.12%: What You Should Know
|
|
Jan 16
|
Merck's Crown Jewel Cancer Drug Keytruda Scores FDA Approval For Third Indication In Cervical Cancer
|
|
Jan 15
|
Merck Animal Health's Fourth Veterinary Wellbeing Study Indicates Progress in Addressing Mental Health Challenges Among Veterinary Teams
|
|
Jan 13
|
Insiders At Merck Sold US$10m In Stock, Alluding To Potential Weakness
|
|
Jan 12
|
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy as Treatment for Patients With FIGO 2014 Stage III-IVA Cervical Cancer
|
|
Jan 12
|
UPDATE 2-Merck's Keytruda combo gets FDA nod for expanded use in cervical cancer
|
|
Jan 10
|
The 3 Best Blue-Chip Stocks to Buy in January 2024
|
|
Jan 10
|
JPM's annual healthcare conference: Here's what's next for GLP-1s and the weight loss market
|
|
Jan 10
|
5 questions facing pharma in 2024
|
|
Jan 9
|
Company News for Jan 9, 2024
|
|
Jan 9
|
Are Robust Financials Driving The Recent Rally In Merck & Co., Inc.'s (NYSE:MRK) Stock?
|